×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SLNO – soleno therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SLNO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
10:00 am
slno
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO
12/10
10:39 am
slno
Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? [Yahoo! Finance]
Low
Report
Is Soleno Therapeutics, Inc. (SLNO) The Cheap Healthcare Stock To Buy Heading Into 2026? [Yahoo! Finance]
12/4
05:23 pm
slno
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
Low
Report
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
12/3
04:17 pm
slno
Soleno Therapeutics Announces the Passing of Board Member William G. Harris [Yahoo! Finance]
Medium
Report
Soleno Therapeutics Announces the Passing of Board Member William G. Harris [Yahoo! Finance]
12/3
04:05 pm
slno
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
Medium
Report
Soleno Therapeutics Announces the Passing of Board Member William G. Harris
12/1
05:48 pm
slno
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
Low
Report
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses
11/30
09:33 pm
slno
Soleno Therapeutics (SLNO): Does Current Valuation Signal Opportunity or Caution for Investors? [Yahoo! Finance]
Low
Report
Soleno Therapeutics (SLNO): Does Current Valuation Signal Opportunity or Caution for Investors? [Yahoo! Finance]
11/25
08:51 am
slno
Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns [Yahoo! Finance]
Low
Report
Soleno Therapeutics (SLNO) Reports Strong Q3 Earnings Despite VYKAT XR Safety Concerns [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
04:01 pm
SLNO
soleno therapeutics, inc.
BEAT
Report
-26.4%
soleno therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
06:50 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Nov 17 Filed by: Norrett Kevin
Medium
Report
Form 4 SOLENO THERAPEUTICS INC For: Nov 17 Filed by: Norrett Kevin
11/19
06:49 pm
slno
Form 3 SOLENO THERAPEUTICS INC For: Nov 17 Filed by: Norrett Kevin
Medium
Report
Form 3 SOLENO THERAPEUTICS INC For: Nov 17 Filed by: Norrett Kevin
11/14
06:35 pm
slno
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Vivo Opportunity Fund Holdings, L.P.
Medium
Report
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Vivo Opportunity Fund Holdings, L.P.
11/14
11:58 am
slno
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: JANUS HENDERSON GROUP PLC
11/13
09:09 am
slno
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
Low
Report
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
11/12
05:21 pm
slno
Form 4 SOLENO THERAPEUTICS INC For: Nov 10 Filed by: Joshi Manher
Low
Report
Form 4 SOLENO THERAPEUTICS INC For: Nov 10 Filed by: Joshi Manher
11/12
05:19 pm
slno
Form 3 SOLENO THERAPEUTICS INC For: Nov 10 Filed by: Joshi Manher
Low
Report
Form 3 SOLENO THERAPEUTICS INC For: Nov 10 Filed by: Joshi Manher
11/12
06:10 am
slno
Form 8-K SOLENO THERAPEUTICS INC For: Nov 10
Medium
Report
Form 8-K SOLENO THERAPEUTICS INC For: Nov 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
10/23
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
34.8%
12/23 Soleno Therapeutics Inc (NASDAQ: SLNO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock. 21.2%
11/27 Form 4 SOLENO THERAPEUTICS INC For: Nov 26 Filed by: Vivo Ventures Fund V, L.P. 18.5%
2/14 Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: FEINBERG LARRY N 17.9%
10/2 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome 17.1%
1/21 Form S-8 SOLENO THERAPEUTICS INC 14.7%
12/9 Form SC 13D/A SOLENO THERAPEUTICS INC Filed by: Vivo Ventures V, LLC 10.7%
11/13 Q3/2019 9/30/2019 EPS 0.030 ZacksConsensus N/A ActVsEst N/A - N/A 10.0%
6/11 Form S-3 SOLENO THERAPEUTICS INC 9.5%
10/28 Form 4 SOLENO THERAPEUTICS INC For: Oct 24 Filed by: Vivo Ventures Fund V, L.P. 9.3%
12/23 Soleno Therapeutics Inc (NASDAQ: SLNO) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $10.00 price target on the stock. 21.2%
11/27 Form 4 SOLENO THERAPEUTICS INC For: Nov 26 Filed by: Vivo Ventures Fund V, L.P. 18.5%
2/14 Form SC 13G/A SOLENO THERAPEUTICS INC Filed by: FEINBERG LARRY N 17.9%
10/2 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome 17.1%
1/21 Form S-8 SOLENO THERAPEUTICS INC 14.7%
12/9 Form SC 13D/A SOLENO THERAPEUTICS INC Filed by: Vivo Ventures V, LLC 10.7%
11/13 Q3/2019 9/30/2019 EPS 0.030 ZacksConsensus N/A ActVsEst N/A - N/A 10.0%
6/11 Form S-3 SOLENO THERAPEUTICS INC 9.5%
10/28 Form 4 SOLENO THERAPEUTICS INC For: Oct 24 Filed by: Vivo Ventures Fund V, L.P. 9.3%
TOP News Decliners
3/12
Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-17.5%
8/3 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -12.4%
12/26 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.7%
1/24 Form 4 SOLENO THERAPEUTICS INC For: Jan 23 Filed by: Yen Kristen -9.3%
7/25 Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome -8.9%
3/11 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference -8.8%
3/4 Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 -8.3%
2/22 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -7.0%
8/21 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.8%
12/11 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.0%
8/3 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. -12.4%
12/26 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.7%
1/24 Form 4 SOLENO THERAPEUTICS INC For: Jan 23 Filed by: Yen Kristen -9.3%
7/25 Soleno Therapeutics Provides Update on Ongoing DESTINY PWS Phase III Trial of DCCR in Prader-Willi Syndrome -8.9%
3/11 Soleno Therapeutics to Present at the 30th Annual Oppenheimer Healthcare Conference -8.8%
3/4 Form 10-K SOLENO THERAPEUTICS INC For: Dec 31 -8.3%
2/22 Soleno Therapeutics Inc (NASDAQ: SLNO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. -7.0%
8/21 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.8%
12/11 Soleno Therapeutics Inc (NASDAQ: SLNO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -6.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: